Drug Research

The Alliance for Regenerative Medicine Launches Standards Coordinating Body to Advance Development and Establishment of Industry-Wide Standards

January 23, 2017

WASHINGTON, DC–(Marketwired – Jan 19, 2017) –   The Alliance for Regenerative Medicine (ARM) today announced the formal launch of the international Standards Coordinating Body for regenerative medicines (SCB), a public-private partnership for coordinating, prioritizing and supporting standards that advances process, measurement and analytical techniques to support the global availability of products across the gene and […]

Newly Created Standards Coordinating Body Seeks to Advance Development and Establishment of Regenerative Medicine Standards

January 23, 2017

WASHINGTON, DC–(Marketwired – Jan 19, 2017) – The international Standards Coordinating Body for regenerative medicines (SCB), in coordination with the Alliance for Regenerative Medicine (ARM), today announced its formal launch as a public-private partnership for coordinating, prioritizing and supporting standards that advances process, measurement and analytical techniques to support the global availability of products across […]

NeuroVive Presents Positive Preclinical Data in Hepatocellular Cancer at HCC Summit

January 19, 2017

LUND, Sweden, Jan. 19, 2017 /PRNewswire/ — NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer data related to the company’s sanglifehrin-based compounds has been accepted for presentation at the scientific conference EASL HCC Summit to take place in Geneva, Switzerland, 2-5 February, […]

Progenra Discovers Novel Immune Oncology Drug

January 17, 2017

MALVERN, Pa.–(BUSINESS WIRE)–Progenra, Inc. announced a new immune-oncology drug whose mechanism differs from available cancer immunotherapies Opdivo and Keytruda. The findings, published by Progenra with Dr. Wayne Hancock, University of Pennsylvania School of Medicine, support a new immune-oncology antitumor strategy by inhibiting USP7, an enzyme that prevents immune activity against cancer in addition to supporting […]

Selonterra Publishes Novel Proprietary Mechanism for APOE4 in Alzheimer’s Disease

January 17, 2017

Belmont, CA, USA January 17, 2017 / B3C newswire / — Selonterra LLC, a biotechnology company discovering therapies for Alzheimer’s disease and Parkinson’s disease announced the publication of the article “Identification of a Nuclear Respiratory Factor 1 Recognition Motif in the Apolipoprotein E Variant APOE4 linked to Alzheimer’s Disease” in Scientific Reports, a peer-reviewed journal […]

New Research Suggests Anti-viral Role for Aravive Biologics’ Anti-AXL Candidate Against ZIKA Virus

January 16, 2017

HOUSTON–(BUSINESS WIRE)–Newly published in vitro research reveals that the ability of ZIKA virus (ZIKV) to infect glial cells in the developing brain is mediated by the Gas6-AXL pathway, and that Aravive Biologic’s engineered decoy AXL receptor, Aravive-S6 (referred to as MYD1 in the publication) can block ZIKV infection by intercepting Gas6 to prevent AXL signaling. […]

10x Genomics Announces Publication of Study in Nature Communications Demonstrating Single Cell Profiling in Leukemia Patients by the Fred Hutchinson Cancer Research Center

January 16, 2017

PLEASANTON, Calif.–(BUSINESS WIRE)–10x Genomics, Inc., a company focused on enabling the mastery of biology by accelerating genomic discovery, today announced the publication of a study enabled by the company’s Chromium™ Single Cell 3’ Solution. This powerful new technology provides robust single-cell expression measurements, allowing the discovery of gene expression dynamics and molecular profiling of individual […]

Regenacy Pharmaceuticals HDAC1,2 Inhibitors Demonstrate Single-agent and Synergistic Activity with Azacitidine (Vidaza®) in Preclinical Models of Acute Myeloid Leukemia

January 13, 2017

BOSTON–(BUSINESS WIRE)–Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation, today announced the publication of results from preclinical studies that demonstrate potent anti-leukemic activities of HDAC1,2-selective inhibitors both as single agents and in combination with azacitidine (Vidaza®) in multiple models of acute myeloid leukemia (AML). The manuscript titled, “Selective inhibitors of […]

3M Drug Delivery Systems announces collaboration with Panacea Pharmaceuticals, Inc. on New Cancer Vaccine

January 13, 2017

PAUL, MN – (Jan. 11, 2017) – Today, 3M Drug Delivery Systems announces a new phase of an ongoing collaboration with Panacea Pharmaceuticals, Inc. in delivering an investigational therapeutic cancer vaccine directly to the dermis via the 3M™ Hollow Microstructured Transdermal System (hMTS). The first patient in the Phase 1 clinical study has been dosed […]

Haplogen’s Novel Antiviral Target Partnered with Evotec Published in ‘Nature’

January 13, 2017

VIENNA & AMSTERDAM & HAMBURG, Germany–(BUSINESS WIRE)–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH (“Haplogen”), a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned […]

MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X-linked Chronic Granulomatous Disease (CGD) Gene

January 13, 2017

GAITHERSBURG, Md., Jan. 12, 2017 /PRNewswire/ — MaxCyte®, Inc., a developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announced today pre-clinical results from a collaborative study with investigators at the National Institutes of Health’s (NIH) National Institute of […]

BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel Poster presentation at ODAC Conference reports potential anti-inflammatory properties of minocycline

January 13, 2017

MENLO PARK, Calif., Jan. 12, 2017 /PRNewswire/ — BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share research findings at this week’s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which suggest that topical minocycline may reduce P. acnes-induced inflammation.   The data will be shared in a […]

Protein Sciences Zika Vaccine Shows Good Results in Preclinical Testing Bio-Manguinhos/Fiocruz joins International Consortium

January 13, 2017

MERIDEN, Conn., Jan. 12, 2017 /PRNewswire/ — Protein Sciences Corporation, a leading vaccine development company and maker of Flublok Influenza Vaccine®, announced today that its lead protein based Zika vaccine candidate had good safety results and induced strong neutralizing antibodies against the Zika virus in preclinical studies. The product is expected to advance into human […]

Kitov Enters Immuno-Oncology Field Through Acquisition of TyrNovo

January 13, 2017

TEL AVIV, Israel, January 12, 2017 /PRNewswire/ —       TyrNovo’s NT219 drug candidate works by overcoming tumors’ cancer drug resistance and would be developed as a combination drug, presenting a new paradigm in cancer therapy NT219 is a novel proprietary dual inhibitor of two major oncogenic pathways (IRS1/2 and STAT3) highly involved in […]

Regenacy Pharmaceuticals HDAC1,2 Inhibitors Demonstrate Single-agent and Synergistic Activity with Azacitidine (Vidaza®) in Preclinical Models of Acute Myeloid Leukemia

January 12, 2017

— Results from studies in multiple in vitro, ex vivo and in vivo preclinical models of AML published online in PLOS ONE – — Regenacy to present at the Biotech Showcase- BOSTON–(BUSINESS WIRE)–Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation, today announced the publication of results from preclinical studies that […]

3M Drug Delivery Systems announces collaboration with Panacea Pharmaceuticals, Inc. on New Cancer Vaccine

January 12, 2017

ST. PAUL, MN – (Jan. 11, 2017) – Today, 3M Drug Delivery Systems announces a new phase of an ongoing collaboration with Panacea Pharmaceuticals, Inc. in delivering an investigational therapeutic cancer vaccine directly to the dermis via the 3M™ Hollow Microstructured Transdermal System (hMTS). The first patient in the Phase 1 clinical study has been […]

Haplogen’s Novel Antiviral Target Partnered with Evotec Published in ‘Nature’

January 12, 2017

VIENNA & AMSTERDAM & HAMBURG, Germany–(BUSINESS WIRE)–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH (“Haplogen”), a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned […]

Genervon Releases ALS, PD and AD Disease-Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm

January 10, 2017

PASADENA, Calif.–(BUSINESS WIRE)–Genervon Biopharmaceuticals LLC (“Genervon”) has published a confidential list of genes associated with Parkinson’s disease (PD 46-59 genes, 2 to 1.5 folds, link: https://f1000research.com/posters/6-28) today during the JP Morgan Healthcare Conference in San Francisco. Mr. Winston Ko has also released a video articulating why Genervon is releasing these confidential neurodegenerative disease-related gene lists […]

Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave® as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections

January 9, 2017

Vienna, Austria, January 09, 2017 / B3C newswire / — Hookipa Biotech AG, an immunotherapy company developing next-generation cancer immune therapeutics and vaccines based on the Company´s proprietary arenavirus vector platforms, announces publication in the January 2017 issue of the peer-reviewed journal Clinical and Vaccine Immunology(1), of data confirming the potential of Hookipa’s HB-101 Vaxwave® […]

Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study

January 9, 2017

LIVONIA, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) — Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of nonalcoholic steatohepatitis (NASH). Gemphire plans to initiate clinical development of gemcabene in NASH/nonalcoholic fatty liver disease (NAFLD) with a Phase 2 […]

Allele to Develop iPSC-Derived Cell Therapies with Focus on Diabetes and Spinal Cord Injury

January 9, 2017

SAN DIEGO–(BUSINESS WIRE)–Allele Biotechnology & Pharmaceuticals, a privately held company, announces that it has officially entered into the development of induced pluripotent stem cell (iPSC)-derived cell therapies after the development plan received strong support by the Scientific Advisory Board and was approved by the Board of Directors in December of 2016. #Allele _Biotech officially enters […]

Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome

January 9, 2017

BASEL, Switzerland, Jan. 6, 2017 /PRNewswire/ — Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced entering into an exclusive worldwide licensing agreement with Duke University to develop RVT-802, a tissue-based therapy for the treatment of complete DiGeorge Syndrome (cDGS), a rare and fatal congenital immunodeficiency disease. In […]

Neovacs to collaborate with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal cancer and ovarian cancer

January 6, 2017

PARIS and BOSTON, Jan. 05, 2017 (GLOBE NEWSWIRE) — Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapies for the treatment of autoimmune diseases, today announced its collaboration with Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada for preclinical development of Neovacs’ VEGF Kinoid, specifically to obtain the proof of […]

Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders

January 6, 2017

Basel, January 06, 2017 – Novartis announced today a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII. The two investigational antisense therapies developed […]

Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight

January 5, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data on the edasalonexent program, a potential disease-modifying therapy for Duchenne muscular dystrophy (DMD). The preclinical data demonstrate that edasalonexent (CAT-1004) and an analog, CAT-1041, oral inhibitors of NF-kB, are effective in ameliorating the dystrophic process in two animal […]

Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Journal of Medicinal Chemistry

January 5, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data on CAT-5571, a novel activator of autophagy and potential oral treatment for cystic fibrosis (CF). The preclinical data demonstrate an increase in CF transmembrane conductance regulator (CFTR) activity and trafficking which are detailed in an article titled “Fatty […]

FEEDBACK